Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1950 1
1951 1
1953 2
1961 1
1962 1
1965 1
1967 1
1968 1
1970 1
1971 1
1974 1
1978 1
1979 5
1980 2
1981 5
1982 2
1983 2
1984 3
1985 7
1986 6
1987 9
1988 6
1989 10
1990 8
1991 9
1992 11
1993 5
1994 5
1995 7
1996 5
1997 7
1998 12
1999 10
2000 12
2001 8
2002 8
2003 6
2004 4
2005 15
2006 8
2007 11
2008 10
2009 7
2010 16
2011 24
2012 9
2013 11
2014 15
2015 29
2016 24
2017 21
2018 21
2019 14
2020 16
2021 27
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

449 results
Results by year
Filters applied: . Clear all
Page 1
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP. Fedoriw A, et al. Among authors: copeland ra. Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27. Cancer Cell. 2019. PMID: 31257072 Free article.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Among authors: copeland ra. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM, Kuntz KW, Keilhack H. Knutson SK, et al. Among authors: copeland ra. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. doi: 10.1073/pnas.1303800110. Epub 2013 Apr 25. Proc Natl Acad Sci U S A. 2013. PMID: 23620515 Free PMC article.
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. Chan-Penebre E, et al. Among authors: copeland ra. Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27. Nat Chem Biol. 2015. PMID: 25915199
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H. Knutson SK, et al. Among authors: copeland ra. Mol Cancer Ther. 2014 Apr;13(4):842-54. doi: 10.1158/1535-7163.MCT-13-0773. Epub 2014 Feb 21. Mol Cancer Ther. 2014. PMID: 24563539
Page LB, Copeland RB. Page LB, et al. Among authors: copeland rb. Dis Mon. 1968 Jan:1-40. Dis Mon. 1968. PMID: 4965919 Review. No abstract available.
Surviving syndemics - Authors' reply.
Fields EL, Copeland R, Hopkins E, Sanders RA, Malebranche DJ. Fields EL, et al. Among authors: copeland r. Lancet. 2021 Jul 10;398(10295):119. doi: 10.1016/S0140-6736(21)01325-8. Lancet. 2021. PMID: 34246345 No abstract available.
New targets in triple-negative breast cancer.
Copeland RL, Kanaan Y. Copeland RL, et al. Nat Rev Cancer. 2021 Dec;21(12):744. doi: 10.1038/s41568-021-00415-4. Nat Rev Cancer. 2021. PMID: 34621048 No abstract available.
Novel targets for parkinsonism-depression comorbidity.
Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL. Tizabi Y, et al. Among authors: copeland rl. Prog Mol Biol Transl Sci. 2019;167:1-24. doi: 10.1016/bs.pmbts.2019.06.004. Epub 2019 Jul 8. Prog Mol Biol Transl Sci. 2019. PMID: 31601399 Review.
449 results